Paul B. Manning
Chairman of the BoardMr. Paul B. Manning is Director at PatientsLikeMe, Inc. from January 2022. He serves as Chairman at Independent Candel Therapeutics, Inc. since July 15, 2021. He serves as Member of the Investment and Capital Market Advisor at Xalud Therapeutics, Inc. He serves as an Independent Director at Liquidia Corporation since December 2020. He serves as Chairman of the Board at Xalud Therapeutics, Inc. He was an Independent Director at Taysha Gene Therapies, Inc. since March 2020 until June 20, 2023 and has been its Board Observer since June 20, 2023. He serves as Chief Executive Officer at PBM Capital Group LLC which he founded in 2010 and served as President. He has been Chairman of PBM Capital Group LLC. He serves as Founder, Chief Executive Officer and President of Revive Pharmaceuticals Inc. Mr. Manning serves as Independent Director at ArcherDx, Inc. since January 2015. He served as a Director of RareGen, LLC from August 2018 until November 2020 and also serves as a Director of other private companies. Since November 2022, Mr. Manning has served as Interim Chief Executive Officer of SalioGen Therapeutics. Mr. Manning founded PBM Products in 1997. He served as Executive Vice President and General Manager of PBM at Perrigo Company Public Limited Company since June 2010. Before that, he held key sales and marketing positions with pharmaceutical companies and founded several companies, including Able Laboratories, PBM Products and Manfam, Inc. He served as Chairman of Dova Pharmaceuticals, Inc. since June 2017 until November 12, 2019 and its Director since September 2016 until November 12, 2019. He has been the Chairman of Verrica Pharmaceuticals Inc. since December 2017 and has been its Director since December 2015. He served as a Director of AveXis, Inc. from April 2014 to May 15, 2018. He serves as Director of Candel Therapeutics, Inc. since November 2018 and served as its Chair of the Board until 2021. He serves as a Board Member of RareGen, Enzymatics Inc. and Tolerion Inc. He serves as a Member of Business Advisory Board at Firefly BioWorks, Inc. He serves as a Director of the National Neurovision Research Institute (NNRI). He served as a Director of Perrigo Corporation. He served as an Independent Director of Concordia International Corp. (formerly, Concordia Healthcare Corp.) from May 15, 2014 to January 2, 2015. He served as a Director of Gen9, Inc. He is the Founder of Focus to Cure Diabetes Foundation. He has Managerial and operational experience in the healthcare industry and as an Investor in healthcare related companies. Mr. Manning is a 1977 graduate of the University of Massachusetts, Amherst, where he earned a B.S. in microbiology.
Positions
- Company NameVerrica Pharmaceuticals Inc.Stock CodeVRCAPositionChairman of the BoardColleagues
- JMJayson M. RiegerPresident, CEO & Director
- PBPaul B. ManningChairman of the Board
- JJJohn J. KirbyInterim Chief Financial Officer
- NLNoah L. RosenbergChief Medical Officer
- DZDavid ZawitzCOO, Chief Legal Officer & Secretary
- ESEugene ScavolaExecutive Vice President of Technical Operations
- MAMark A. PrygockiIndependent Director
- LFLawrence F. EichenfieldIndependent Director
- DNDiem NguyenIndependent Director
- Company NameCandel Therapeutics, Inc.Stock CodeCADLPositionIndependent ChairmanColleagues
- PTPaul-Peter TakPresident, CEO & Director
- CSCharles SchochSenior VP, CFO, Treasurer & Secretary
- FBFrancesca BaroneChief Scientific Officer
- STSeshu TyagarajanChief Technical & Development Officer
- TJTheodore JenkinsVice President of Investor Relations & Business Development
- EJEdward John BenzMember of Research Advisory Board & Independent Director
- RMRenee M. GaetaIndependent Director
- NLNicoletta LoggiaIndependent Director
